Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.57 |
| ▸ | HPGD | P15428 | 6/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11572587 | 0.87 | ALDH1A1 (0.51) | TSHRKMT2AALDH1A1KDM4EHPGD | |
| SCHEMBL530857 | 0.81 | KMT2A (0.68) | TSHRKMT2AALDH1A1KDM4EHPGD | |
| SCHEMBL1638701 | 0.80 | ALDH1A1 (0.62) | TSHRKMT2AALDH1A1KDM4EHPGD | |
| SCHEMBL11393249 | 0.80 | KDM4E (0.55) | TSHRKMT2AALDH1A1KDM4EHPGD | |
| SCHEMBL8889074 | 0.79 | KMT2A (0.80) | TSHRKMT2AALDH1A1KDM4EHPGD | |
| SCHEMBL9624375 | 0.78 | KMT2A (0.67) | TSHRKMT2AALDH1A1KDM4EHPGD | |
| SCHEMBL220059 | 0.78 | KMT2A (0.72) | TSHRKMT2AALDH1A1KDM4EHPGD | |
| SCHEMBL19221685 | 0.77 | HTT (0.72) | TSHRKMT2AALDH1A1KDM4EHPGD | |
| SCHEMBL2451515 | 0.77 | BCAT2 (0.61) | KMT2AALDH1A1MEN1MAPK1GAA | |
| SCHEMBL14856070 | 0.76 | TSHR (0.74) | TSHRKMT2AALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022072-B2 | Azolylmethylidenehydrazine derivative and use thereof | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20100190754-A1 | AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-2168951-A1 | AZOLYLMETHYLENEHYDRAZINE DERIVATIVE AND USE THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190754-A1 | AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF | ARSA, AHR, HRH2 | TSHR 2973/4885KMT2A 1190/4885ALDH1A1 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.